Inflexion acquires CDMO Upperton

The GP said it has made a substantial investment in the pharmaceutical services business. The stake was a majority, according to a source familiar with the situation. 

Inflexion has invested via its Enterprise Fund V, which closed in May 2019 at GBP 400m. It makes growth and buyout deals in the UK lower mid-market, investing between GBP 10m and GBP 75m. 

Upperton conducts formulation and analytical development and clinical trial manufacturing services for small to mid-sized pharma clients, often in the early stage of clinical trials. 

Inflexion said it will support Upperton in expanding scale and capabilities, starting with the build of a new, larger manufacturing facility. The sponsor said this will allow Upperton to support the later stages of clinical trials. 

The GP's other healthcare investments include Rosemont Pharmaceuticals, a British liquid medicine manufacturer, which it carved out from listed US company Perrigo in June 2020 for GBP 156m.  

It also carved out CNX Therapeutics in August 2021 from Sunovion; owns a minority stake in vaccination provider ELCG; and a majority stake in scientific data disseminator Pharmaspectra. 

Inflexion declined to comment.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Healthcare
• Buyouts
• UK / Ireland
• Inflexion Private Equity